

Towards Patient-centered Stewardship of Research Data and Research Participant Recruitment with Blockchain Technology

1 Peng Zhang^{1*}, Chris Downs⁴, Nguyen Thanh Uyen Le³, Cory Martin⁴, Paul Shoemaker⁴, Clay
2 Wittwer⁴, Luke Mills², Liam Kelly², Stuart Lackey⁴, Douglas C. Schmidt², Jules White²

3 ¹Vanderbilt University Medical Center, Nashville, TN, USA

4 ²Dept. of Electrical Engineering & Computer Science, Vanderbilt University, Nashville, TN, USA

5 ³Owen Graduate School of Management, Vanderbilt University, Nashville, TN, USA

6 ⁴Solaster, Nashville, TN, USA

7 * **Correspondence:**

8 Corresponding Author

9 peng.zhang@vanderbilt.edu

10 **Keywords:** patient-centered, data, data sharing, interoperability, blockchain, distributed ledger
11 technology, research studies

12 **Abstract**

13 Significant effort is required to recruit and validate patients for research studies. Researchers are
14 typically limited to patients that they have a physical touchpoint with (e.g., patients at VUMC). This
15 physical access limitation reduces the research attention that patients with rare diseases with little
16 geographic concentration and poorer patients in rural areas receive. This paper explores the use of
17 mobile computing and blockchain technology to provide validation of research studies and their data
18 usage, advertisement of research studies, collection of research data, and sharing of data across
19 studies. The paper presents key challenges of using blockchains and mobile computing to solve these
20 issues, competing architectural approaches, and the benefits/trade-offs of each approach.

21 **1 Introduction**

22 A critical component of healthcare research is finding and recruiting participants in research studies
23 and ensuring that researchers have sufficient data to make decisions regarding patient qualification to
24 participate in a study. For example, simple information, such as the drugs that a patient is allergic to
25 or if they have a specific health condition in their medical record, is essential to making recruitment
26 decisions. If a single piece of important information is missing, it can lead researchers to make
27 inappropriate decisions regarding participant selection.

28
29 As a consequence of the need for access to detailed patient information, patient recruitment typically
30 begins in clinical settings, such as hospitals, where researchers have direct access to detailed medical
31 record information. For example, researchers may work with a specific clinic within a medical center
32 and educate providers about their study and the types of patients that they are looking for as
33 participants. The clinic will have detailed medical record information and a face-to-face touchpoint
34 with patients to facilitate recruitment of patients that meet the participation eligibility criteria of the
35 study.

36
37 An emerging architectural model that is gaining interest is putting patients at the center of the
38 stewardship of their medical data [1]. Patients already have the right to see and move their data
39 between providers, so it seems a natural fit that they should have mechanisms to see and move the

40 electronic copies of their medical data, rather than only printed copies. With a patient-centered
41 stewardship model, patients always have direct access to their own data from all providers and can
42 delegate access at any time. This architecture is fundamentally different from the current model [2]
43 where patients do not have direct access to the totality of their data and must individually request
44 portions of the data from each provider, assemble the necessary portfolio, and then deliver the
45 combined pieces to another provider.

46
47 An early manifestation of this patient-centered stewardship model is the ability for Apple's HealthKit
48 [3] to import medical records from Epic [4], which is one of the most widely used electronic medical
49 record systems in the US, into a user's mobile device. HealthKit directly imports data using the FHIR
50 standard [5] into a patient's Apple mobile device. Once on a patient's mobile device, a patient can
51 choose to share their health records with additional apps on the device, which may in turn deliver the
52 data to other medical providers or researchers.

53
54 A key question that arises in this new patient-centered data stewardship model is if there are
55 opportunities to expand how patients are recruited into research studies. In particular, given that
56 patients now have direct control over electronic copies of their medical records and the ability to
57 share this access with apps on their devices, can researchers recruit patients directly through those
58 apps? With this model, researchers would produce an app that can read medical record data directly
59 from a patient's HealthKit records and determine if a patient potentially meets the eligibility criteria
60 for a study. If a patient matches a research study, they could be notified of the match and given the
61 option to directly communicate with researchers conducting the study to determine if they can
62 participate. Moreover, they could directly transmit needed medical record information from
63 HealthKit to the researchers to further assist their participant selection decision.

64
65 If successful, this patient-centered model could help facilitate research study recruitment in terms of
66 recruiting cost, data management cost, and research time beyond the typical settings, such as clinics,
67 that have access to the needed medical records to perform the preliminary stage of filtering to match
68 patients to research studies. There are several published studies that analyze the effectiveness of
69 recruitment for medical researches, such as [6]-[8], and they each focused on different research
70 purposes, which created a wide variance of the cost for recruitment stage. Generally, computerized
71 support systems would help save significant recruiting cost compared to traditional clinic-based
72 approaches [9]. In addition, computerized support systems have considerable potential for reducing
73 the timeline and increase efficiency of data management process of medical research studies [10].
74 Another trend that is impacting patient care is the rise in production of non-traditional health-related
75 data, such as records of self-reported meals, step counts from fitness trackers, and momentary
76 assessments of mood or pain from patients. This data, which is typically not part of the medical
77 record today, is increasingly demonstrating value to researchers in understanding diagnostic and
78 disease management processes. For example, meal logs can aid researchers in understanding how
79 effectively patients are self-managing chronic conditions, such as diabetes.

80
81 Whereas traditional medical records are directly captured through the provider in the electronic
82 medical record system, this newer exercise tracker and other non-traditional data is typically captured
83 through mobile devices, IoT devices in the home (e.g., wifi scales), and through online services (e.g.,
84 social networks). The data collection mechanisms span a vast array of apps, devices, and services,
85 few of which are trusted or certified by any healthcare entities.

86
87 Now, with the new patient-centered data stewardship model, this non-traditional data is accessible
88 side-by-side within HealthKit with traditional medical record data. This combining of both types of

89 data in a single location offers the potential for supporting many types of innovative research, such as
90 research on patient reported outcomes or large-scale studies of lifestyle on health.

91
92 A second interesting question related to research studies and this new patient-centered data
93 stewardship model is if the current research data sharing and reuse model can be expanded to both
94 incorporate this non-traditional data and put patients in control of how the data is shared with other
95 researchers. With the current research data ownership model, patients typically do not have the
96 ability to easily access and share the research data from them with other researchers. The lack of
97 control of their data limits the impact that patient's research data can have on other research studies
98 and keeps researchers, rather than patients, in control of the data.

99
100 Since patients now have access to both their traditional health records and non-traditional health-
101 related data on the same device, patients can potentially join research studies with little or no face-to-
102 face interaction with researchers. In the new model, patients would feed their medical records and
103 non-traditional data to researchers through the HealthKit conduit. Although detailed clinical studies
104 requiring high-fidelity, close physician monitoring of health, and administration of new medications
105 or interventions may not be possible, studies that focus on the impact of non-traditional data on
106 health or vice-versa could be feasible without direct contact with the participant.

107
108 Moreover, if participants use HealthKit to capture and provide their medical record and non-
109 traditional health data with researchers, it is feasible that they could simultaneously share this data
110 with multiple research studies or redistribute previously captured data to new research studies that
111 could benefit from it. There are certainly many studies where access to the details of how the data
112 was collected, such as how lab tests were performed, would render this type of model from
113 ineffective. However, we posit that there are many studies, such as observational studies that research
114 how diet affects a person's blood sugar level or how sleep affects one's mood, where this model is
115 not only feasible but offers unique new research opportunities.

116
117 In this paper, we explore key research challenges to realizing this vision, although we fully
118 acknowledge the presence of many other types of challenges. Through our detailed analysis of the
119 research challenges, we have found that Distributed Ledger Technology possesses attributes that
120 make it a promising solution to realizing this new model for research study recruitment and sharing
121 of research data across studies. After careful analysis of the research challenges and promising
122 attributes of distributed ledgers, we propose an initial open architecture for study participant
123 recruitment and data sharing in the emerging patient-centered data stewardship model.

124
125 The remainder of this paper is organized as follows. Section 2 provides a motivating healthcare
126 research example to demonstrate the need for and trends toward a patient-centric data stewardship
127 model. Section 3 presents key challenges in clinical research recruitment today. Section 4 proposes a
128 decentralized architecture based on Distributed Ledger Technology for facilitating data sharing in the
129 research participant recruitment process. Section 5 discusses related research on platforms for
130 improving the recruitment process for research studies and work that leverages distributed ledger
131 technology to felicitate healthcare data sharing. Section 6 presents concluding remarks and
132 summarizes our key lessons learned.

133 **2 Motivating Healthcare Research Example**

134 As a motivating example for the exploration, we use an example of the management of a serious
135 chronic condition that most commonly manifests in adolescent patients, namely, Type 1 Diabetes
136 Mellitus (T1DM). T1DM is an autoimmune disease where the pancreas produces little or no insulin,

137 which is critical to help the human body manage blood sugar levels. The treatment of this condition
138 relies on patients to perform self-management tasks, such as self-measurement of blood glucose and
139 self-administration of insulin, to avoid life-threatening complications [11].

140
141 Despite physiological traits like blood glucose levels and carbohydrates intake that are commonly
142 used as clinical indicators of how T1DM is controlled, recent studies [12] have shown that
143 psychosocial behavior in adolescent patients with T1DM can significantly affect the adherence to
144 diabetes regimen in this population. As a result, much more diverse data, such as fatigue level, mood,
145 location, and social context, can be collected to observe the behavior or further analyzed to provide
146 timely intervention to poor self-management behavior [13]. These data can easily be collected in or
147 near real-time using Internet of Things (IoT) devices like smartphones, Bluetooth-powered glucose
148 meters, and environmental sensors. They can complement traditional electronic health records (EHR)
149 to provide a more comprehensive view of patient health status by including potentially influential
150 variables from outside clinical settings [14].

151
152 Unlike EHR systems that have served healthcare for decades, emerging IoT-based systems that
153 record health-related activities (such as self-observed behavior data or sensor-recorded environmental
154 triggers) have not yet been rigorously tested and certified to integrate with high-fidelity data like
155 provider-documented EHRs. There is a lot of distrust towards mobile app/IoT providers from
156 physicians and certified EHR system vendors, causing delays in the data integration process. In the
157 case of adolescents with T1DM, patients often have to maintain a journal that logs their daily
158 diabetes management routine. The journal may locate separately from, for instance, an app that
159 monitors daily psychosocial/behavioral traits for the same patient. It is highly likely that neither the
160 journal nor the app data would be linked to the patient's health records, which can create potential
161 problems, such as inconsistencies in the medical history or misinformation, particularly when that
162 patient changes provider.

163
164 Current healthcare systems are known to be provider-centric as forced by vendor-locked systems.
165 These systems operate and only enable cross-system communications upon the establishment of trust
166 relationships between vendors and providers. In the modern society where a lot of healthcare efforts
167 are gradually becoming decentralized thanks to IoT technologies, the centralization model that is
168 trust-dependent will become less effective and create more overhead for patients to manage care [15].

169 **3 Challenges in Recruitment for Clinical Research**

170 Despite the importance of clinical research and continuous efforts to increase clinical research
171 participation, many challenges exist in the recruitment process and are multi-faceted, creating
172 barriers for researchers to complete their studies. This section discusses four such challenges,
173 including recruiting costs, participant discovery of research studies, data reuse, and data ownership
174 distribution.

175

176 **3.1 Recruiting Costs**

177 Medical research is a long-term investment. Depending on the scope of the research, the timeline will
178 vary. DiMasi and Grabowski estimated the average length of time from the start of clinical testing to
179 marketing is 90.3 months in the pharmaceutical sector and 97.7 months for the biotechnology sector
180 [16]. Lengthy timelines directly impact the cost of capital for the medical projects and increase the
181 financial burden for researchers and investors because it is considered as opportunity costs associated
182 with foregone investments over the researching period.

183
184 The recruitment process alone accounts, on average, for nearly 30% of total clinical trial time (around
185 30 months) [17]. During this process, resources required to recruit and enroll participants must be
186 sustained, including but not limited to recruitment and coordinating staff, equipment, facilities,
187 advertisements, etc., all of which contribute to significant recruiting costs. Recruiting a large enough
188 pool of participants to validate the statistical result of medical research has always been a difficult
189 task for healthcare researchers. More than 81% of clinical trials are delayed because researchers
190 cannot recruit enough participants for the studies [18]. In particular, when analyzing 374 cases at
191 Oregon Health & Science University, 31% of clinical research studies enrolled 0–1 subject before
192 being terminated, which creates a waste of over \$1 million per year [19].

193
194 More recently however, computerized support systems have proven to be advantageous in recruiting
195 participants on a large scale at a lower cost. A study involving healthy volunteers among different
196 recruiting methods has shown that costs per enrolled subject were lower for the EHR patient portal
197 (\$113) than letters (\$559) or phone calls (\$435) [20]. In addition, another study in Australia tested
198 the effect of leveraging a technical platform (social media) in healthcare recruiting process. The
199 results showed that the technical platform was more cost-effective, especially in the earlier stages of
200 the studies (the cost to obtain a screened respondent: AUD\$22.73 vs AUD\$29.35; cost to obtain an
201 eligible respondent: AUD\$37.56 vs AUD\$44.77) [21]. These analyses show that integrating
202 technology that can accelerate the recruitment process of medical research, which would in turn save
203 the recruiting costs and total costs of the studies tremendously.

204

205 **3.2 Participant Discovery of Research Studies**

206 Recruitment of patients with a physical touchpoint leads to an institution-centric advertising model.
207 Because clinical studies are controlled by separated institutions, participants need to put in
208 considerable effort to find the studies that match their health status and relate to a medical condition
209 they want to involve in. Popular resources include the website of National Institutes of Health (NIH)
210 [22], third-party “search engine” for proprietary market research [23], and other tools that are not
211 specifically designed for clinical research recruitment (e.g., Amazon Mechanical Turk [24]).
212 Most of these resources are spread across multiple information channels aiming to improve the
213 publicity of research studies, but the distributed information may become scattered and outdated or
214 cause confusion to potential research volunteers. Furthermore, the eligibility criteria to participate in
215 a study can contain complex clinical terminologies that are hard to interpret by participants without
216 advanced clinical knowledge. It is also impractical for volunteers to reach out to clinical experts for
217 every trial they are interested in due to the large number of ongoing trials. As a result, potential
218 volunteers may be discouraged to inquire about or participate in research studies.

219 **3.3 Data Reuse Challenges**

220 Reusing and aggregating clinical data have been proven effective for facilitating the discovery of new
221 knowledge and the processes of healthcare [25-26]. Recognizing these benefits, some governmental
222 organizations including NIH [27] and the National Science Foundation (NSF) [28] have started to
223 support data sharing and openness in clinical research. In contrast, data sharing is not a popular
224 practice in reality as it should be. There are many concerns related but not limited to the ownership of
225 reused data, the quality of the data, and legal compliance. As the cost of recruiting patient and
226 acquiring the data is high, researchers usually prioritize clinical workflow support, legal compliance,
227 and their research purposes over the quality of the data for reuse. Documenting how data is acquired

228 and transformed, storing data in a universal format, and finding accessible repositories to share the
229 data are very time-consuming.

230
231 According to a study on biomedical data sharing [29], research subjects' privacy is the most common
232 reason why researchers are reluctant to share data. Other factors include publication competition,
233 unnecessary data/manuscript audit and misuse/misinterpretation of the data. In addition, there is
234 currently no proper mechanism to accredit researchers who contribute or share the data. In some
235 cases, these researchers will either be included as a co-author on a publication, get recognition in the
236 acknowledgement section of the publication, or be cited in the bibliography. Some researchers may
237 not receive any acknowledgement for sharing their data at all.

238
239 Another data sharing concern is the loss of information and data context. Compared to the enormous
240 number of variables present in clinical research, especially on the metadata level, data warehouses
241 store only a fraction of the total data collected. Moreover, acquiring the core dataset alone may not be
242 sufficient for other researchers to understand and reuse the data effectively. Although current EHR
243 systems are designed for ease of use by researchers, many data fields still exist in unstructured format
244 that hinder effective data sharing, and there has not been a highly reliable approach to explore this
245 data. At the same time, inconsistency in data standards and formats in structured data also prevent
246 researchers from sharing and learning from other data [30].

247
248 For researchers who do participate in data sharing, they are required to obtain consent from enrolled
249 subjects for all studies. In this case, researchers may choose to request additional consent to sharing
250 data. In practice, however, this is hard to implement as researchers are not able to foresee the purpose
251 and results of secondary analysis that may come up much later than the time consent is obtained. In
252 contrast to researchers' legal compliance, patients and volunteers are much more open to data
253 sharing. According to a study, 93% patients were very or somewhat likely to allow their own data to
254 be shared with university scientists, and 82% were very or somewhat likely to share with scientists in
255 for-profit companies [31].

256 **3.4 Distributing Control Over Data Ownership**

257 According to health information policies and regulations, patients possess the ownership of their
258 health data and should be requested for consent when their data is used for secondary analysis. In
259 current practice, patients may provide consent by physically signing a paper form or electronically
260 signing a document online. Electronic consent forms can be used to more efficiently identify the
261 original patient providing the consent if the forms are associated with a patient in the database. Paper-
262 based consent forms, on the other hand, require much more effort to store (e.g., scanning and upload
263 an electronic copy of the physical forms and manually entering data into the system) and may be lost
264 or illegible along the process, making re-consent more difficult to establish [32].

265
266 It is therefore important to create a platform that values privacy and is able to easily trace back to the
267 appropriate patient to re-consent, which may further encourage sharing and reuse of research data. It
268 is also critical to ensure that data is shared and reused responsibly. Mechanisms like peer review or
269 patient review of proposals for reusing research data can protect the subjects and the original
270 researchers who acquired the data. With a careful design, it is possible to incorporate these desired
271 features into the data sharing platform to allow a more flexible and direct way to obtain consent for
272 data sharing.

273 4 A Distributed Ledger Architecture for Research Participant Recruitment and Research 274 Data Sharing

275 How do we leverage the potential trend towards patient-centric stewardship of medical data to
276 improve research matching, control of research data, and incorporation of non-traditional data
277 sources accessible to mobile devices? We present an architecture that publishes or redirects research
278 studies into a public distributed ledger that is used by researchers and research participants for
279 finding mutual matches. The goal of this ledger for research studies is to have a virtually centralized
280 location for hosting and discovering research studies that is accessible from mobile apps and reduces
281 recruitment costs. The expectation is that marketing and other costs to engage patients with the ledger
282 would be amortized across the thousands of studies published there and help address Challenges 3.1
283 and 3.2.

284
285 A second component of the approach is that individual users would download the catalog of studies
286 and match against them directly on their mobile devices. This model would facilitate scaling up
287 matching by not requiring researchers to already have a clinical relationship with the user and still be
288 able to match against clinical data. Further, the patient can prospectively discover and match against
289 studies privately, helping to address Challenge 3.2.

290
291 A final key component of the approach is that patients directly discover studies and disseminate their
292 data to these studies. Through this model, patients control dissemination of their data, which allow
293 them to send their data to as many studies as they wish in a self-direct manner and flat structure,
294 enabling greater potential research data reuse. For example, a patient can provide the same set of data
295 to ten studies that desire it without relying on the first researcher that they provide the data to share it
296 with the other nine studies. The decision of how data, owned by the participant, is subsequently
297 distributed is up to the participant and not the researcher that receives the data. Further, later studies
298 that publish requests for the same data as a prior study have the potential to be matched against the
299 same set of original participants from an earlier study and receive the original data if the participants
300 self-provide consent.

301
302 The remainder of this section provides an overview of the key attributes of distributed ledgers and
303 then provides an architecture for exploiting properties of distributed ledgers to design these
304 components. The section covers both the benefits and trade-offs of the architecture.

305 4.1 Distributed Ledger Technology Overview

306 Distributed Ledger Technology (DLT) as implemented with a Blockchain data structure was first
307 considered by Haber and Stornetta in 1991 within their landmark paper, “How to Time-Stamp a
308 Digital Document,” as an approach consisting of a chained data structure and a node-based
309 distribution network [33]. Faced with a future where an overwhelming majority of media would
310 become digitized, they considered the ease with which creation and modification dates could be
311 tampered with. As a result, a proposal was made to develop a data structure whereby a “...chain of
312 time-stamps...” [33] consisting of the utilization of cryptographically strong hash functions would
313 be utilized along with a consensus-based mechanism for verification within a trustless environment.
314 This “chain” served as a starting point for the most popular data structure implementation of the
315 Ledger called Blockchain. Along with foundational principles in peer-to-peer distribution, this also
316 provided a framework for what was to come in 2008 when an as-yet-unidentified individual known
317 by the name Satoshi Nakamoto distributed what would become Blockchain’s most popular
318 implementation in the form of the paper entitled, “Bitcoin: A Peer-to-Peer Electronic Cash System”
319 [34]. At its heart, DLT consists of two primary components: a blockchain data structure and a peer-

320 to-peer network. In order to more fully understand these components, we will break down each in
321 turn providing more relevant details along the way.

322
323 Within DLT, the blockchain data structure serves to represent the Ledger. As an illustrating
324 example, Alice records a piece of data containing her name and other personal information to a text
325 document and saves the file afterwards. She would like to ensure that the information in this file is
326 not altered by anyone with proof. Given the ease with which a digital file can be copied and
327 modified, how might Alice certify in some provable way that her file is the original file owned by
328 her? To expand on this scenario, another person Bob may want to perform this same task but with
329 his name and information stored in the file. How can both versions of the document be protected
330 against tampering and proven that they represent two distinct states entered at different points in
331 time? This is where a blockchain data structure is useful for the purposes of creating a tamper-proof
332 Ledger.

333
334 Blockchain consists of n nodes that are linked together in a cryptographically protected manner.
335 During the formation of the chain, each node consists of data provided by some client application
336 (such as a name or other personal data) and a cryptographic hash of the data in the node that precedes
337 it (except for the case of the root node, where no data precedes it). The hash algorithm, also called
338 “the workhorses of modern cryptography,” [35] is fundamental to this technology. Hashing
339 algorithms have several key traits, including an input that can be of an arbitrary size, a fixed-size
340 output space, and efficiency [36] with respect to computation.

341
342 Together, these properties use the information stored in the Ledger (and whatever other data might be
343 relevant at the time of hashing - such as a timestamp) to produce a long string of letter and number
344 combinations that represents a snapshot of that data that is computationally infeasible to reverse and
345 also proves mathematically that the data is unaltered. If the same long string representation is
346 embedded into the next link in the chain (along with the important source data), by hashing those bits
347 together, a cryptographically irreversible bond can be produced from one record to another.

348 Within DLT, the distributed nature is commonly implemented through a peer-to-peer networking
349 structure. More specifically, the blockchain data structure described above that serves to form the
350 Ledger is distributed among p number of peers for the purpose of independent validation of the data
351 in the blockchain in order to establish mathematically provable trust within an otherwise trustless
352 environment.

353
354 Given the often-times decentralized nature of the distribution network, node identities are largely
355 anonymous. As a result, there is a challenge in establishing trust with an anonymous party whose
356 transactions within the Ledger look identical no matter if they are a bad or good actor. Trust is an
357 important factor within any network whereby verifiable truth must be established that a specified bit
358 of data has been recorded into a Ledger and has not been tampered with. As the blockchain-based
359 Ledger has been distributed among some number of peer nodes, each individual peer holds the same
360 exact version of that Ledger. How to establish trust within this anonymous space? What prevents
361 bad-actors from colluding to tamper with the data in the Ledger and still certifying its original
362 veracity? Why is it important to distribute the Ledger in the first place? The answer to these
363 questions lies within a specific activity that typically occurs within a decentralized distribution
364 network; namely, consensus.

365
366 Consensus mechanisms are designed to achieve agreement with respect to the veracity as it pertains
367 to a particular activity within a system. This has been identified as “a fundamental problem of fault-
368 tolerant distributed computing” [37] – to achieve reliability in distributed systems, protocols are

369 needed that enable the system as a whole to continue to function despite the failure of a limited
370 number of components. For a Distributed Ledger, the reliability of the system is directly related to
371 the trust within that system. The failure in the system directly relates to bad actors whose primary
372 goal is to undermine that trust in return for personal gain. In order to achieve trust through
373 consensus, several algorithms have been designed for this purpose including Proof of Work [34],
374 Proof of Stake [38], and Practical Byzantine Fault Tolerance [39]. Each algorithm achieves
375 consensus through different mechanisms, which have both positive and negative attributes to them
376 [40], leaving the choice of which algorithm to use to the architects of the system and their stated
377 goals.

378
379 DLT allows a user to record data in an immutable manner through the use of a blockchain data
380 structure while also obtaining verification of that fact through the use of decentralized and distributed
381 consensus algorithms. As a result of these two broad properties, this technology presents a
382 compelling architecture with respect to maintaining robust transactional integrity for our solution
383 described herein.

384 **4.2 A DLT-Based Architecture for Research Participant Recruitment and Research Data** 385 **Sharing**

386 Figure 1 shows an architecture for a patient-centric stewardship model of research study matching
387 and clinical data sharing. The goals of this architecture are to: (1) allow patients to perform research
388 study matching using their health data on their local devices, (2) create immutable public descriptions
389 of research studies and the data they consume, (3) provide patients with the ability to directly send
390 their health data from clinical and non-traditional data sources (e.g., apps) to researchers, and (4)
391 allow patients to control and acknowledge the sharing of their research data.

392
393 The key emerging change in the healthcare market that makes this architecture feasible is the move
394 towards patient-centric stewardship of data on their mobile devices. As shown in Step 1 of Figure 1,
395 patients can directly import their health data from a provider onto their mobile phone. Apple devices
396 provide the HealthKit API and access to Epic EHRs via FHIR.

397
398 The rest of the architecture shown in Figure 1 focuses on enabling devices to discover research
399 studies and find researchers in need of their data. The core idea is that patients have the ultimate
400 control of where their data goes and when it may be reused in other research studies. The distributed
401 ledger component of the architecture facilitates the discovery of research studies by creating a public
402 record of all studies and a precise description of the data consumed by each study. In order to gain
403 access to research participant health data, researchers must publish the description of their study
404 (Step 2) into the ledger where it can be discovered by patient devices (Steps 3 & 4). Based on the
405 data description, participants choose from the lists of studies that they potentially match or that would
406 benefit from data that they have already provided to a research study in the past to share data with
407 (Step 5).




Figure 1. An Architecture for Enabling Patient-Centric Stewardship of Research Data Using a Distributed Ledger

408
409
410

411 4.3 Distributed Ledgers and Research Participant Privacy

412 Using a public distributed ledger for an application that facilitates both the recruitment of research
413 participants, as well as the sharing of research data offers a number of advantages. Those advantages
414 can be grouped into three distinct categories: data security, transaction control, and reliability. When
415 contemplating data security for a research participant use case, it is important to note that in a public
416 ledger, the records of all transactions are public and immutable. That is not to say that the underlying
417 medical data is public, but simply that the descriptions recording the access of data are public. Once a
418 blockchain operation occurs and the transaction is recorded, that record is immutable and will
419 propagate to all the peer nodes in the decentralized network. A study published into the blockchain
420 cannot be retracted and will provide a permanent clear record of the data it consumed. If a research
421 study is completed, however, it will be flagged as completed and will not be used for participant
422 matching.

423

424 One architectural possibility would be to have research participants directly record study enrollment
425 directly in the blockchain. An individual who agreed to participate in a research study would have a
426 permanent record of any and every study that accessed the participant's data. Likewise, a study would
427 be able to see what studies a participant has joined. For research studies however, having a public
428 record of participation is problematic because it violates privacy rules regarding research
429 participation. To overcome this challenge, the architecture shown in Figure 1 leverages the
430 distributed ledger only for advertising studies and recording the data that those studies consume. As
431 shown in Step 2 of Figure 1, researchers publish a description of the study into the ledger, but
432 participation in studies is handled completely outside of the blockchain.

433

434 With patients stewarding their own medical data, they have the freedom to determine whether to
435 participate in each research study. Within each study, a patient who is willing to participate would
436 also be able to decide exactly which data to share with a particular study. This gives patients
437 complete control over the use of their medical data. One approach would be to use the blockchain to

438 facilitate the transfer of the data itself, but this is problematic for the same reason as recording
439 participation in the blockchain – it would inevitably violate research participant privacy.

440
441 In the architecture shown in Figure 1, all joining of studies and sending of data is performed outside
442 of the blockchain and directly between the participant and researcher. Step 5 directly sends data to a
443 research data management platform, such as REDCap [41]. In other work, we have relied on direct
444 submission of data from participants’ devices to REDCap. The key problem that this architecture
445 overcomes is finding participants and solving the technical challenges of getting their clinical data
446 into REDCap from their provider. Further, this architecture allows submission of data from IoT or
447 other sources accessible to the device (e.g., Bluetooth Glucometers, Wifi Scales, etc.).

448
449 Although a participant may match a study based on an analysis done on the patient’s device,
450 researchers may still have other criteria that are difficult or impossible to publish into the blockchain
451 for matching. During the direct communication between the participant and the researcher, the
452 researcher may choose not to use the participant’s data. In these cases, the data collected from the
453 participant would need to be discarded by the researcher. A downside of the architecture is that there
454 is no way to enforce destruction of participant data – although this is also the case in current practice.
455 The architecture still relies on institutional controls, such as policies and Institutional Review Boards
456 [42], to ensure researchers act ethically.

457
458 The nature of blockchain networks provides a third important aspect: reliability. Participants and
459 study providers must be able to trust that the chain of published research studies is valid and will not
460 disappear. Since blockchains are a network of independent nodes, there is not a single point of
461 failure, nor is one node able to control the entire network. Before transactions are recorded, they must
462 be validated according to the consensus mechanism for that network. Once a transaction is validated,
463 it is recorded and propagated to the individual nodes such that the loss of one or more nodes, or
464 control of one or more nodes will not impact the validity of the transaction records on the entire
465 network.

466 **4.4 Research Study Descriptions and Matching Criteria**

467 All research studies added to the blockchain include a request for participants who have a particular
468 set of medical characteristics. Patients are notified of the availability of the study by their device and
469 can choose to validate their medical data against the requested characteristics. If validation is
470 successful, patients can choose to submit the validation (along with additional participation data) to
471 the study to initiate their participation, as shown in Step 5 of Figure 1. The study provider would see
472 a transaction indicating a successful match, along with the participation data necessary to include the
473 patient in the study and validate the match. This chain of transactions could also include the ability
474 for participants to monetize the use of their data, or generally for their participation, if such were a
475 requirement. All these transactions take place directly between the participant’s device and the
476 researcher using a standard platform, such as REDCap.

477
478 In order to expedite the matching process, studies are defined by three sets of characteristics that may
479 be matched against: boolean conditions (ex: asthma, hypertension), enumerated characteristics (ex:
480 hair color, relationship status), and ranged characteristics (ex: desired age range, desired weight
481 range, how long a condition has been diagnosed). These characteristics are provided by researchers
482 conducting the studies. These simplifications allow for primitive boolean tests to decide whether the
483 criteria for a study match the healthcare data provided by a given patient. In order for a patient to

484 qualify for a given study, they must have a complete (100%) satisfaction of study criteria via a simple
485 iterative key-value boolean loop.

486

487 Because each study adheres to the same language of matching criteria, relationships can be formed
488 between the studies. A key benefit of the matching language is that it facilitates condensing the
489 matching rules across multiple research studies into a single network of rules using the Rete
490 algorithm [43]. The Rete algorithm is designed to take in a knowledge base of facts (e.g., the
491 participants' clinical and IoT data) and efficiently determine which rules from a set should fire (e.g.,
492 which research studies match). Each rule is defined by a set of matching conditions and an action. In
493 the proposed architecture, the *conditions* are the research study matching criteria and the *action* is
494 proposing to the user a possible research study is matched. The algorithm shares conditions between
495 rules in a directed acyclic graph so that conditions are only evaluated once regardless of how many
496 rules include the condition. For example, the condition of the participant having blood pressure above
497 a threshold would be evaluated once, regardless of how many research studies relied on the same
498 matching condition.

499

500 The entire body of published studies can be used to collect matching conditions and build an acyclic
501 matching graph using Rete. A graph analyzes the necessary conditions of one study in conjunction
502 with the sufficient conditions of another, allowing for the elimination of more complex study
503 matching should a patient's data deem them unqualified for a simpler study with a subset of the
504 matching criteria. For example, if a patient fails to qualify for Study A, which requires participants to
505 be aged 30-40, then the graph will immediately eliminate Study B which requires participants aged
506 33-37 with hypertension. In this way, consideration of a simple study can cascade the elimination of
507 countless nodes/studies in the graph, drastically improving performance on patient-study matching.
508 The drawback of the dependency graph is the time required to generate the graph. A few
509 considerations mitigate this cost. First, the graph need only be generated on the server, thus each
510 mobile device does not have individual time expended for the graph. This generation of the graph
511 server-side is captured in Step 4 of Figure 1. Second, the proposed generation of the dependency
512 graph is to trigger a new server-side build of the graph once daily (optimally during non-peak usage
513 hours) to update the graph with new studies added to the blockchain and completed studies marked as
514 no longer recruiting. As such, the dependency graph method best optimizes average-user
515 performance - and very clearly increases scalability of the matching algorithm. The dependency
516 graph need only be built once, and then can be shared amongst all mobile device sessions.

517 **4.5 Mediating Mobile Device Blockchain Access**

518 Although there is significant discussion on enabling patient data sovereignty using blockchains, very
519 few of these discussions address a major fundamental problem – access to the blockchain. Interacting
520 with a blockchain requires the setup of a node in the distributed ledger, which can be a complicated
521 endeavor. For example, most Bitcoin [34] users rely on a third-party wallet service [44] to hold their
522 cryptocurrency, run the required distributed ledger node, and perform trades on their behalf. Despite
523 the appearance of complete decentralization and control by the user, the user is actually dependent on
524 the wallet service for access and is not completely in control.

525

526 A similar problem arises in using a blockchain to publish research studies. Blockchains are difficult
527 to access from a mobile device without an intermediate service, equivalent to a wallet service for
528 Bitcoin. Directly accessing and validating transactions on a blockchain is both time and energy
529 consuming, which makes downloading the entire ledger and validating it on a mobile device
530 problematic.

531

532 The architecture shown in Figure 1 handles this access issue by introducing a *Study Aggregator* as
533 shown between Steps 3 & 4. The study aggregator manages access to the distributed ledger and
534 watches for the publication of new studies into the ledger. When new studies are published, it
535 validates and aggregates them into a comprehensive catalog of available studies.

536 A further function of the study aggregator is to use the Rete algorithm to build the acyclic research
537 study matching graph described in Section 5.4. Both interacting with the blockchain and constructing
538 this acyclic graph are potentially expensive operations that are isolated on the server-side aggregator,
539 where power consumption and processing power are much less problematic. Furthermore,
540 aggregation and graph construction costs can be paid once and amortized across all mobile device
541 accesses rather than paid on each individual device.

542

543 The downside of this approach is that it introduces a potential central point of failure and control in
544 the system. However, there are two key reasons that this is not a significant concern. First, any
545 number of study aggregators can be run independently by arbitrary organizations. There is no need
546 for a single study aggregator in the system. Each research institution can run their own study
547 aggregator and provide aggregation services to research participants' mobile devices.
548 Second, the failure of an aggregator only temporarily cuts off access to the study catalog for the
549 mobile devices currently relying on that specific aggregator. A mobile device can use multiple
550 aggregators for redundant access or consensus. Even if one aggregator fails, a participant can
551 discover and use other aggregators. Since the aggregator only produces a derived copy of the
552 research matching graph, the original research study data is still immutably and reliably stored in the
553 distributed ledger despite aggregator failures.

554 **4.6 Scalability & Privacy Trade-offs for On-device Matching**

555 An additional consideration of the study aggregator is how it impacts trust, scalability, and privacy
556 [45]. Any time that trust in the aggregator is reduced, it improves privacy at the expense of
557 scalability. The critical privacy and scalability tuning of the system is done in how trust relationships
558 are established with study aggregators and how much work is offloaded to the aggregator.

559

560 The proposed architecture does not dictate how trust is established in a particular study aggregator.
561 Our belief is that research institutions already manage the establishment of trust with research
562 participants and are likely the best conduit to establish these trust relationships. For example,
563 research institutions could create a trust aggregator and advertise its address on their existing
564 websites or through face-to-face interactions with clinicians. Alternatively, non-profits organized
565 around specific interests, such as diseases (e.g., American Cancer Society), could operate and publish
566 aggregators.

567

568 Mobile devices rely on the acyclic matching graphs produced by the study aggregators. There is an
569 opportunity to improve scalability and performance on the mobile device by pruning the acyclic
570 graph at the aggregator to reduce the data transfer to the mobile device and the amount of work
571 matching against the graph. Any pruning of the graph at the aggregator reduces the workload on the
572 mobile device, which will be the limiting factor in the scalability of the system if the entire matching
573 graph for every published study needs to be transferred to each mobile device.

574

575 To improve scalability, mobile devices can either: 1) send a subset of their data to an aggregator to
576 perform intelligent pruning or 2) subscribe to aggregators that publish graphs pruned to a specific set
577 of interests. For example, a device can send a limited set of less-sensitive and semi-anonymous data,

578 such as age and weight, to the server and receive a pruned subset of the graph that has potentially
579 viable studies that can be determined with further matching on the device. The benefit of this
580 approach is that matching can be more easily scaled. The downside is that the approach inherently
581 reduces the overall privacy of the system by requiring some set of data from the mobile device.
582 An alternative approach to improve scalability is to subscribe to an aggregator that publishes a
583 pruned graph that only contains studies relevant to a specific interest. For example, an aggregator
584 might only publish studies relevant to a specific disease. This approach also has a privacy trade-off in
585 that subscription to the aggregator implies interest in a disease or set of diseases, which may have
586 privacy implications (e.g., interest in cancer implies a cancer diagnosis).

587
588 In either approach, it is expected that once a match is made, the mobile device will begin direct
589 communication with the study organization to verify the match. As part of this process, an important
590 secondary verification will be performed, which is that the mobile device will download a description
591 of the matching criteria directly from the research organization to ensure that the matching graph
592 from the aggregator was accurate. If there is any discrepancy between the matching logic for the
593 study published by the aggregator or the research study site, which would indicate tampering by one
594 of the two entities, the mobile device will discard the match and not continue. This secondary
595 matching is not full-proof and does indicate possible benefits to use a different aggregator than the
596 organization operating a given study.

597
598 We performed an initial analysis of the scalability issues regarding research study matching on
599 participants' devices versus on the server in terms of time and data transfer. The key scalability
600 limitation that we found for on-device matching is shown in Figure 2. As the number of studies
601 grows, the amount of data that has to be transmitted to the mobile device also grows. The analysis
602 was conducted by randomly generating matching graphs representing varying numbers of studies and
603 calculating their total size in kilobytes. We developed a compact representation of the graphs –
604 although it is certainly possible to improve efficiency – and measured the overall amount of data that
605 would need to be transmitted to the mobile device. As shown in the figure, the overall size of the
606 matching graph is proportional to the number of research studies, which are expected to continually
607 grow over time. With our test graph representation, 20,000 studies required transmitting roughly 48
608 megabytes to a client. Real-world studies may have more overlap in the matching conditions and
609 there may be much more efficient representations that could lead to smaller graph sizes. This size,
610 however, is similar in size to an average app download on a mobile device.

611
612 Figure 2 also shows the significant scalability improvement that can be achieved by sending data to
613 the server and performing matching there. The bars labeled “Server” show the total data transfer
614 required if the mobile device completely trusts the aggregator to perform matching on its behalf and
615 sends data needed for matching to the server. As shown in the results, there are multiple orders of
616 magnitude of overhead added when the mobile device does not trust the aggregator to perform
617 matching versus when it does.




Figure 2. Matching Criteria Graph Size vs. Total Studies

618
619
620

621 The potential to have aggregators publish a pruned graph also illustrates a potential security issue.
622 The mobile devices rely on the aggregator to publish an accurate graph of the studies in the
623 blockchain. If an aggregator lies, they have the potential to perform a number of attacks from their
624 trusted position. One potential way to overcome this issue is to use cryptographic signing of studies
625 so that mobile devices can verify the authenticity of the study before beginning a direct interaction
626 with a research due to a possible match. However, like any approach that relies on public key
627 infrastructure, key distribution and trust is a significant issue. Indubitably, a set of trusted roots will
628 be needed to provide signing chains that can be used to prove that a specific research study originated
629 with a specific institution and researcher. The precise architecture of this distribution model is left to
630 future work but is expected to look similar to how SSL certificates are issued for websites [46].

631

632 Although the architecture has focused on scalability regarding matching, a secondary scalability
633 concern is the metadata regarding research studies. Each research study includes data on the
634 organization running the study, the matching criteria, the data collected by the study, and the purpose
635 of the study. This data is not accounted for in Figure 2 and could be substantial. There are several
636 architectural approaches to handling the scalability issues surrounding metadata that each have their
637 own privacy-scalability trade-offs.

638

639 Our approach to handling metadata is to publish a non-blockchain address for retrieving the metadata
640 directly from the organization hosting the study. For example, an academic institution could host web
641 pages for each study with the metadata describing the study and include the URL for the metadata in
642 the study description published to the blockchain. This approach eliminates the need for the
643 aggregator to publish the catalog of metadata and reduces the data transfer to the mobile device. The
644 aggregator only publishes the URL to retrieve the metadata and a signed hash of the study metadata
645 that it read from the blockchain. The mobile device would compare the signed hash to the hash that it
646 calculates for the metadata after retrieving it from the provided URL. Again, a key distribution
647 mechanism would be needed and is not covered in the current work.

648 5 Related Work

649 This section presents prior research on the architectures and platforms designed to improve research
650 study recruitment and summarizes recent work on using DLT and related technologies to enable data
651 sharing in the healthcare space.

652 **5.1 Research Participant Recruitment**

653 To date, there has been a number of efforts on providing patients, volunteers, and researchers with
654 resources and information on clinical studies covering a large number of conditions and diseases.
655 ClinicalTrials.gov [47], a web-based, centralized clinical trial repository, is one of the most popular
656 platforms where researchers register their trials publicly so that participants can easily access the
657 study information. It is the largest clinical trial registry in the U.S. with over 300,000 trials reported.
658 It does not contain all clinical studies, however, because some studies are not required to be
659 registered. ResearchMatch.org [48] is another web-based, centralized platform for matching
660 volunteers with actively recruiting trials and therefore maintains a subset of trials from
661 ClinicalTrials.gov. ResearchMatch.org has a large number of volunteer users with their self-reported
662 information, such as conditions and medications, that is used to provide basic trial recommendations
663 based on a trial's primary conditions targeted. Besana et al. [49] proposed a domain-specific semantic
664 ontology to represent data from patient health records and to evaluate patients' eligibility to clinical
665 trials. Another increasingly popular strategy to improve recruitment is the use of clinical trial alert
666 tools that automatically apply eligibility criteria to EHRs in order to identify potential participants
667 proactively [50].

668 **5.2 DLT-Based Healthcare Data Sharing Frameworks**

669 Due to the increasing popularity of DLT given its unique properties, many based healthcare data
670 sharing frameworks based on distributed ledgers have been introduced in literature [51]. For
671 example, the MedRec system [52] was proposed as a blockchain implementation of a healthcare data
672 warehouse that facilitates clinical data sharing. The FHIRChain framework [53] was designed to
673 enable data sharing between various healthcare data sources using the FHIR protocol and
674 incorporated a number of key technical requirements of an interoperable healthcare service. Peterson
675 et al. [54] presented a healthcare blockchain with a single centralized source of trust for sharing
676 patient data, introducing "Proof of Interoperability" based on conformance to the FHIR protocol as a
677 means to ensure network consensus. More recently, Xia et al. [55] described a blockchain-based
678 system called "MeDShare" for enabling medical data sharing among cloud service providers.
679 OpTrak, a DLT-based architecture used for exchanging and tracking opioid prescriptions is also
680 proposed in [56].

681 **6 Concluding Remarks**

682 Given the fundamental importance of capturing a complete picture of a patient's healthcare history,
683 why do researchers and medical institutions not have a universal system to share the needed research
684 data? Currently, healthcare information is generally captured using electronic medical records by
685 each individual provider. However, a variety of factors, ranging data format incompatibility, differing
686 approaches to labs, and challenges in identifying patients has led to a model where healthcare data
687 does not flow freely between all providers.

688
689 Overcoming the challenges of healthcare data exchange are going to require allowing patients to
690 easily control and move their data between providers and to get their non-traditional data from apps
691 and other sources into their medical record. However, moving to a patient-centered medical data
692 stewardship model faces immense challenges if all of the data stewardship falls solely on the medical
693 institutions, ranging from the existing issues with data formats and labs, to additional barriers to how

694 all patients, not just the most technically sophisticated, can durably store and authorize access to their
 695 data in a secure way. The underlying healthcare networks are inherently decentralized, so there is
 696 also a challenge of figuring out how to move to provider a patient-centered model without a central
 697 authority to mediate exchange and mandate decisions.

698
 699 Doctors also face the daunting challenge of trying to diagnose patients from a combination of
 700 symptoms and medical history. A patient's medical record provides essential clues to a provider that
 701 help, both to diagnose patients more accurately and also help eliminate possibilities and often
 702 associated diagnostics or procedures that may expose patients to additional risk. Whenever medical
 703 information is missing, the impact can be longer, less accurate, and more risking diagnostic
 704 processes.

705
 706 This paper explores the conflicting forces that make achieving a patient-centered stewardship hard
 707 and investigates how the emerging capabilities of decentralized ledgers may help to alleviate some of
 708 these conflicts. A key goal of the work is to understand where DLT can serve a role in a patient-
 709 centered model, what problems it solves, what new problems it introduces, and what problems still
 710 remain unaddressed. Further, through the investigation, the paper analyzes distributed ledger
 711 architectural options and how they resolve conflicting forces at different levels.

712 The final component of the paper is a prototype architecture for using distributed ledgers to facilitate
 713 a patient-centered data stewardship model. The architecture draws insights from the detailed
 714 exploration and architectural trade-offs analysis to prescribe a set of proposed standards for using
 715 DLT in this domain.

716 7 **References**

- 717 1. Kahn, James S., Veenu Aulakh, and Adam Bosworth. "What it takes: characteristics of the
 718 ideal personal health record." *Health affairs* 28, no. 2 (2009): 369-376.
- 719 2. Beard, Leslie, Rebecca Schein, Dante Morra, Kumanan Wilson, and Jennifer Keelan. "The
 720 challenges in making electronic health records accessible to patients." *Journal of the American*
 721 *Medical Informatics Association* 19, no. 1 (2011): 116-120.
- 722 3. "Apple." Apple. Accessed June 14, 2019. <https://www.apple.com/>.
- 723 4. "Epic." Epic. Accessed June 14, 2019. <https://www.epic.com/>.
- 724 5. Bender, Duane, and Kamran Sartipi. "HL7 FHIR: An Agile and RESTful approach to
 725 healthcare information exchange." In *Proceedings of the 26th IEEE International Symposium*
 726 *on Computer-Based Medical Systems*, pp. 326-331. IEEE, 2013.
- 727 6. Lovato, Laura C., Kristin Hill, Stephanie Hertert, Donald B. Hunninghake, and Jeffrey L.
 728 Probstfield. "Recruitment for controlled clinical trials: literature summary and annotated
 729 bibliography." *Controlled clinical trials* 18, no. 4 (1997): 328-352.
- 730 7. Yancey, Antronette K., Alexander N. Ortega, and Shiriki K. Kumanyika. "Effective
 731 recruitment and retention of minority research participants." *Annu. Rev. Public Health* 27
 732 (2006): 1-28.
- 733 8. Gul, Raisa B., and Parveen A. Ali. "Clinical trials: the challenge of recruitment and retention of
 734 participants." *Journal of clinical nursing* 19, no. 1-2 (2010): 227-233.
- 735 9. Kaushal, Rainu, Kaveh G. Shojania, and David W. Bates. "Effects of computerized physician
 736 order entry and clinical decision support systems on medication safety: a systematic
 737 review." *Archives of internal medicine* 163, no. 12 (2003): 1409-1416.
- 738 10. Garg, Amit X., Neill KJ Adhikari, Heather McDonald, M. Patricia Rosas-Arellano, P. J.
 739 Devereaux, Joseph Beyene, Justina Sam, and R. Brian Haynes. "Effects of computerized
 740 clinical decision support systems on practitioner performance and patient outcomes: a
 741 systematic review." *Jama* 293, no. 10 (2005): 1223-1238.

- 742 11. Borchers, Andrea T., Raivo Uibo, and M. Eric Gershwin. "The geoepidemiology of type 1
743 diabetes." *Autoimmunity reviews* 9, no. 5 (2010): A355-A365.
- 744 12. Mulvaney, Shelagh A., Korey K. Hood, David G. Schlundt, Chandra Y. Osborn, Kevin B.
745 Johnson, Russell L. Rothman, and Kenneth A. Wallston. "Development and initial validation of
746 the barriers to diabetes adherence measure for adolescents." *Diabetes research and clinical
747 practice* 94, no. 1 (2011): 77-83.
- 748 13. Zhang, Peng, Douglas Schmidt, Jules White, and Shelagh Mulvaney. "Towards precision
749 behavioral medicine with iot: Iterative design and optimization of a self-management tool for
750 type 1 diabetes." In *2018 IEEE International Conference on Healthcare Informatics (ICHI)*, pp.
751 64-74. IEEE, 2018.
- 752 14. Zhang, Peng, Jules White, and Douglas Schmidt. "Architectures and Patterns for Leveraging
753 High-Frequency, Low-Fidelity Data in the Healthcare Domain." In *2018 IEEE International
754 Conference on Healthcare Informatics (ICHI)*, pp. 463-464. IEEE, 2018.
- 755 15. Zhang, Peng. "Architectures and Patterns for Moving Towards the Use of High-frequency,
756 Low-fidelity Data in Healthcare." PhD diss., Vanderbilt University, 2018.
- 757 16. DiMasi, Joseph A., and Henry G. Grabowski. "The cost of biopharmaceutical R&D: is biotech
758 different?." *Managerial and decision Economics* 28, no. 4 - 5 (2007): 469-479.
- 759 17. Reuters, Thomson. "CMR international pharmaceutical R&D factbook." Thomson Reuters,
760 London (2012).
- 761 18. Nasser, Ms Nariman, Deborah Grady, and C. William Balke. "Commentary: Improving
762 participant recruitment in clinical and translational research." *Academic medicine: journal of
763 the Association of American Medical Colleges* 86, no. 11 (2011): 1334.
- 764 19. Kitterman, Darlene R., Steven K. Cheng, David M. Dilts, and Eric S. Orwoll. "The prevalence
765 and economic impact of low-enrolling clinical studies at an academic medical center."
766 *Academic medicine: journal of the Association of American Medical Colleges* 86, no. 11
767 (2011): 1360.
- 768 20. Samuels, Mary H., Robert Schuff, Peter Beninato, Adriel Gorsuch, James Dursch, Sarah Egan,
769 Bridget Adams, Kate F. Hollis, Rachel Navarro, and Timothy E. Burdick. "Effectiveness and
770 cost of recruiting healthy volunteers for clinical research studies using an electronic patient
771 portal: a randomized study." *Journal of clinical and translational science* 1, no. 6 (2017): 366-
772 372.
- 773 21. Frandsen, Mai, Megan Thow, and Stuart G. Ferguson. "The effectiveness of social media
774 (Facebook) compared with more traditional advertising methods for recruiting eligible
775 participants to health research studies: a randomized, controlled clinical trial." *JMIR research
776 protocols* 5, no. 3 (2016): e161.
- 777 22. "NIH Clinical Center: Patient Recruitment at the NIH Clinical Center." National Institutes of
778 Health. Accessed June 14, 2019. <https://www.cc.nih.gov/recruit>.
- 779 23. "Clinical Trial Resources." CenterWatch. Accessed June 14, 2019.
780 <https://www.centerwatch.com/>.
- 781 24. Buhrmester, Michael, Tracy Kwang, and Samuel D. Gosling. "Amazon's Mechanical Turk: A
782 new source of inexpensive, yet high-quality, data?." *Perspectives on psychological science* 6,
783 no. 1 (2011): 3-5.
- 784 25. Chen, B., and A. J. Butte. "Leveraging big data to transform target selection and drug
785 discovery." *Clinical Pharmacology & Therapeutics* 99, no. 3 (2016): 285-297.
- 786 26. Kreuzthaler, Markus, Stefan Schulz, and Andrea Berghold. "Secondary use of electronic health
787 records for building cohort studies through top-down information extraction." *Journal of
788 biomedical informatics* 53 (2015): 188-195.

- 789 27. Majumder, Mary A., Christi J. Guerrini, Juli M. Bollinger, Robert Cook-Deegan, and Amy L.
790 McGuire. "Sharing data under the 21st Century Cures Act." *Genetics in Medicine* 19, no. 12
791 (2017): 1289.
- 792 28. Jiacui, Yang Shujuan Chen. "Dissemination and Sharing of Research Results: A Review of
793 Anglo-American Funding Program Data Management Plan [J]." *Journal of Intelligence* 12
794 (2012).
- 795 29. Federer, Lisa M., Ya-Ling Lu, Douglas J. Joubert, Judith Welsh, and Barbara Brandys.
796 "Biomedical data sharing and reuse: Attitudes and practices of clinical and scientific research
797 staff." *PloS one* 10, no. 6 (2015): e0129506.
- 798 30. Richesson, Rachel L., and Jeffrey Krischer. "Data standards in clinical research: gaps, overlaps,
799 challenges and future directions." *Journal of the American Medical Informatics Association* 14,
800 no. 6 (2007): 687-696.
- 801 31. Mello, Michelle M., Van Lieou, and Steven N. Goodman. "Clinical trial participants' views of
802 the risks and benefits of data sharing." *New England Journal of Medicine* 378, no. 23 (2018):
803 2202-2211.
- 804 32. Taichman, Darren B., Joyce Backus, Christopher Baethge, Howard Bauchner, Peter W. De
805 Leeuw, Jeffrey M. Drazen, John Fletcher et al. "Sharing clinical trial data: a proposal from the
806 International Committee of Medical Journal Editors." *Annals of internal medicine* 164, no. 7
807 (2016): 505-506.
- 808 33. Haber, Stuart, and W. Scott Stornetta. "How to time-stamp a digital document." In *Conference*
809 *on the Theory and Application of Cryptography*, pp. 437-455. Springer, Berlin, Heidelberg,
810 1990.
- 811 34. Nakamoto, Satoshi. "Bitcoin: A peer-to-peer electronic cash system," [http://bitcoin.org/bitcoin.](http://bitcoin.org/bitcoin.pdf)
812 [pdf](http://bitcoin.org/bitcoin.pdf)." (2008).
- 813 35. Schneier, Bruce. "Cryptanalysis of MD5 and SHA: Time for a New Standard." *Computerworld*
814 19 (2004).
- 815 36. Narayanan, Arvind, Joseph Bonneau, Edward Felten, Andrew Miller, and Steven Goldfeder.
816 *Bitcoin and cryptocurrency technologies: A comprehensive introduction*. Princeton University
817 Press, 2016.
- 818 37. Fischer, Michael J., Nancy A. Lynch, and Michael S. Paterson. *Impossibility of distributed*
819 *consensus with one faulty process*. No. MIT/LCS/TR-282. MASSACHUSETTS INST OF
820 TECH CAMBRIDGE LAB FOR COMPUTER SCIENCE, 1982.
- 821 38. Buterin, Vitalik. "Ethereum white paper." *GitHub repository*(2013): 22-23.
- 822 39. Castro, Miguel, and Barbara Liskov. "Practical Byzantine fault tolerance." In *OSDI*, vol. 99,
823 pp. 173-186. 1999.
- 824 40. Zhang, Peng, Douglas C. Schmidt, Jules White, and Abhishek Dubey, "Consensus Mechanisms
825 and Information Security Technologies." In *Role of Blockchain Technology in IoT*
826 *Applications*. 1st ed. Vol. 15. Elsevier, 2019.
- 827 41. Harris, Paul A., Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, and Jose
828 G. Conde. "Research electronic data capture (REDCap)—a metadata-driven methodology and
829 workflow process for providing translational research informatics support." *Journal of*
830 *biomedical informatics* 42, no. 2 (2009): 377-381.
- 831 42. Lincoln, Yvonna S., and William G. Tierney. "Qualitative research and institutional review
832 boards." *Qualitative inquiry* 10, no. 2 (2004): 219-234.
- 833 43. Forgy, Charles L. "Rete: A fast algorithm for the many pattern/many object pattern match
834 problem." In *Readings in Artificial Intelligence and Databases*, pp. 547-559. Morgan
835 Kaufmann, 1989.
- 836 44. Antonopoulos, Andreas M. *Mastering Bitcoin: unlocking digital cryptocurrencies*. " O'Reilly
837 Media, Inc.", 2014.

- 838 45. Zhang, Peng, Michael A. Walker, Jules White, Douglas C. Schmidt, and Gunther Lenz.
839 "Metrics for assessing blockchain-based healthcare decentralized apps." In 2017 IEEE 19th
840 International Conference on e-Health Networking, Applications and Services (Healthcom), pp.
841 1-4. IEEE, 2017.
- 842 46. Ellison, Carl, Bill Frantz, Butler Lampson, Ron Rivest, Brian Thomas, and Tatu Ylonen. SPKI
843 certificate theory. No. RFC 2693. 1999.
- 844 47. Zarin, Deborah A., Tony Tse, Rebecca J. Williams, Robert M. Califf, and Nicholas C. Ide.
845 "The ClinicalTrials.gov results database—update and key issues." *New England Journal of*
846 *Medicine* 364, no. 9 (2011): 852-860.
- 847 48. Harris, Paul A., Kirstin W. Scott, Laurie Lebo, NikNik Hassan, Chad Lighter, and Jill Pulley.
848 "ResearchMatch: a national registry to recruit volunteers for clinical research." *Academic*
849 *medicine: journal of the Association of American Medical Colleges* 87, no. 1 (2012): 66.
- 850 49. Besana, Paolo, Marc Cuggia, Oussama Zekri, Annabel Bourde, and Anita Burgun. "Using
851 semantic web technologies for clinical trial recruitment." In *International Semantic Web*
852 *Conference*, pp. 34-49. Springer, Berlin, Heidelberg, 2010.
- 853 50. Heinemann, Stephanie, Sabine Thüring, Sven Wedeken, Tobias Schäfer, Christa Scheidt-Nave,
854 Mirko Ketterer, and Wolfgang Himmel. "A clinical trial alert tool to recruit large patient
855 samples and assess selection bias in general practice research." *BMC medical research*
856 *methodology* 11, no. 1 (2011): 16.
- 857 51. Zhang, Peng, Douglas C. Schmidt, Jules White, and Gunther Lenz. "Blockchain technology use
858 cases in healthcare." In *Advances in Computers*, vol. 111, pp. 1-41. Elsevier, 2018.
- 859 52. Azaria, Asaph, Ariel Ekblaw, Thiago Vieira, and Andrew Lippman. "Medrec: Using
860 blockchain for medical data access and permission management." In 2016 2nd International
861 Conference on Open and Big Data (OBD), pp. 25-30. IEEE, 2016.
- 862 53. Zhang, Peng, Jules White, Douglas C. Schmidt, Gunther Lenz, and S. Trent Rosenbloom.
863 "FHIRChain: applying blockchain to securely and scalably share clinical data." *Computational*
864 *and structural biotechnology journal* 16 (2018): 267-278.
- 865 54. Peterson, Kevin, Rammohan Deeduvanu, Pradip Kanjamala, and Kelly Boles. "A blockchain-
866 based approach to health information exchange networks." In *Proc. NIST Workshop*
867 *Blockchain Healthcare*, vol. 1, pp. 1-10. 2016.
- 868 55. Xia, Q. I., Emmanuel Boateng Sifah, Kwame Omono Asamoah, Jianbin Gao, Xiaojiang Du,
869 and Mohsen Guizani. "MeDShare: Trust-less medical data sharing among cloud service
870 providers via blockchain." *IEEE Access* 5 (2017): 14757-14767.
- 871 56. Zhang, Peng, Breck Stodghill, Cory Pitt, Cavin Briody, Douglas C. Schmidt, Jules White, Alan
872 Pitt, and Kelly Aldrich. "OpTrak: Tracking Opioid Prescriptions via Distributed Ledger
873 Technology." *International Journal of Information Systems and Social Change (IJSSC)* 10, no.
874 2 (2019): 45-61.